The eagerly awaited McCAVE trial failed to demonstrate a relevant advantage of combined ANG-2 and VEGF blockade with vanucizumab, a dual humanized monoclonal antibody binding both, VEGF and ANG-2, compared to bevacizumab when both drugs were combined with mFOLFOX-6 in previously untreated metastatic colorectal cancer (31). Here, VEGFA is linked to metastatic colorectal cancer.